1. Home
  2. GAIN vs CTMX Comparison

GAIN vs CTMX Comparison

Compare GAIN & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gladstone Investment Corporation Business Development Company

GAIN

Gladstone Investment Corporation Business Development Company

HOLD

Current Price

$14.23

Market Cap

558.3M

Sector

Finance

ML Signal

HOLD

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$4.44

Market Cap

596.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GAIN
CTMX
Founded
2005
2008
Country
United States
United States
Employees
70
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
558.3M
596.2M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
GAIN
CTMX
Price
$14.23
$4.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
10
Target Price
$14.75
$11.90
AVG Volume (30 Days)
348.1K
9.4M
Earning Date
05-12-2026
03-16-2026
Dividend Yield
10.68%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$76,201,000.00
Revenue This Year
$9.07
N/A
Revenue Next Year
$7.32
$27.22
P/E Ratio
$4.38
$22.58
Revenue Growth
N/A
N/A
52 Week Low
$11.42
$0.40
52 Week High
$15.25
$8.21

Technical Indicators

Market Signals
Indicator
GAIN
CTMX
Relative Strength Index (RSI) 57.85 44.37
Support Level $13.69 $3.55
Resistance Level $14.57 $6.20
Average True Range (ATR) 0.35 0.60
MACD 0.06 -0.07
Stochastic Oscillator 80.00 3.23

Price Performance

Historical Comparison
GAIN
CTMX

About GAIN Gladstone Investment Corporation Business Development Company

Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to achieve and grow current income by investing in debt securities of established businesses; provide the stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: